DeepRare, an AI system, improved diagnostic accuracy for rare diseases compared to existing tools and physicians.
2
The system integrates over 40 tools and databases, providing evidence-based reasoning to enhance diagnostic efficiency.
3
DeepRare achieved higher Recall@1 scores than comparator models, with 69.1% for phenotype and genetic data tasks.
4
In direct comparisons, DeepRare outperformed experienced physicians, achieving 64% Recall@1 versus 55%.
5
The system is designed for patients suspected of rare diseases, not for general screening, with noted limitations.
AACE Endocrine AI
is published by Conexiant under a license arrangement with the American Association of Clinical Endocrinology, Inc. (AACE®). The ideas and opinions expressed in
AACE Endocrine AI do not necessarily reflect those of Conexiant or AACE. For more information, see Policies.